Menu
| 41. | Sopyllo, K; Erickson, AM; Mirtti, T Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer Journal Article In: Cancers, 13 (4), 2021, ISSN: 2072-6694. Links | iCAN PI: Mirtti, Tuomas @article{c9507d9ed1c240a0af59bbddd80fa189, title = {Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer}, author = {Sopyllo, K; Erickson, AM; Mirtti, T}, editor = {Mirtti, Tuomas}, doi = {10.3390/cancers13040628}, issn = {2072-6694}, year = {2021}, date = {2021-01-01}, journal = {Cancers}, volume = {13}, number = {4}, publisher = {MDPI}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 42. | Mars, N; Widen, E; Kerminen, S; Meretoja, T; Pirinen, M; Parolo, PD; Palta, P; Havulinna, A; Palotie, A; Kaprio, J; Joensuu, H; Daly, M; Ripatti, S The role of polygenic risk and susceptibility genes in breast cancer over the course of life Journal Article In: Nature Communications, 11 (1), 2020, ISSN: 2041-1723. Abstract | Links | iCAN PI: Ripatti, Samuli @article{9309770d03dc41e8a6cba0c40c5fcafd, title = {The role of polygenic risk and susceptibility genes in breast cancer over the course of life}, author = {Mars, N; Widen, E; Kerminen, S; Meretoja, T; Pirinen, M; Parolo, PD; Palta, P; Havulinna, A; Palotie, A; Kaprio, J; Joensuu, H; Daly, M; Ripatti, S}, editor = {Ripatti, Samuli}, doi = {10.1038/s41467-020-19966-5}, issn = {2041-1723}, year = {2020}, date = {2020-01-01}, journal = {Nature Communications}, volume = {11}, number = {1}, publisher = {Nature Publishing Group}, abstract = {Polygenic risk scores (PRS) for breast cancer have potential to improve risk prediction, but there is limited information on their utility in various clinical situations. Here we show that among 122,978 women in the FinnGen study with 8401 breast cancer cases, the PRS modifies the breast cancer risk of two high-impact frameshift risk variants. Similarly, we show that after the breast cancer diagnosis, individuals with elevated PRS have an elevated risk of developing contralateral breast cancer, and that the PRS can considerably improve risk assessment among their female first-degree relatives. In more detail, women with the c.1592delT variant in PALB2 (242-fold enrichment in Finland, 336 carriers) and an average PRS (10-90(th) percentile) have a lifetime risk of breast cancer at 55% (95% CI 49-61%), which increases to 84% (71-97%) with a high PRS (>90(th) percentile), and decreases to 49% (30-68%) with a low PRS (}, keywords = {}, pubstate = {published}, tppubtype = {article} } Polygenic risk scores (PRS) for breast cancer have potential to improve risk prediction, but there is limited information on their utility in various clinical situations. Here we show that among 122,978 women in the FinnGen study with 8401 breast cancer cases, the PRS modifies the breast cancer risk of two high-impact frameshift risk variants. Similarly, we show that after the breast cancer diagnosis, individuals with elevated PRS have an elevated risk of developing contralateral breast cancer, and that the PRS can considerably improve risk assessment among their female first-degree relatives. In more detail, women with the c.1592delT variant in PALB2 (242-fold enrichment in Finland, 336 carriers) and an average PRS (10-90(th) percentile) have a lifetime risk of breast cancer at 55% (95% CI 49-61%), which increases to 84% (71-97%) with a high PRS (>90(th) percentile), and decreases to 49% (30-68%) with a low PRS ( |
| 43. | Kasanen, H; Hernberg, M; Makela, S; Bruck, O; Juteau, S; Kohtamaki, L; Ilander, M; Mustjoki, S; Kreutzman, A Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients Journal Article In: Cancer Immunology, Immunotherapy, 69 (5), pp. 717–730, 2020, ISSN: 0340-7004. Links | iCAN PI: Mustjoki, Satu @article{1a446a11fe86456394180837ae39975e, title = {Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients}, author = {Kasanen, H; Hernberg, M; Makela, S; Bruck, O; Juteau, S; Kohtamaki, L; Ilander, M; Mustjoki, S; Kreutzman, A}, editor = {Mustjoki, Satu}, doi = {10.1007/s00262-020-02497-9}, issn = {0340-7004}, year = {2020}, date = {2020-01-01}, journal = {Cancer Immunology, Immunotherapy}, volume = {69}, number = {5}, pages = {717--730}, publisher = {Springer}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 44. | Malani, D; Yadav, B; Kumar, A; Potdar, S; Kontro, M; Kankainen, M; Javarappa, KK; Porkka, K; Wolf, M; Aittokallio, T; Wennerberg, K; Heckman, CA; Murumagi, A; Kallioniemi, O KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia Journal Article In: Leukemia, 34 (10), pp. 2780–2784, 2020, ISSN: 0887-6924. Links | iCAN PI: Porkka, Kimmo @article{48bf0850471949bd877bf3b7a609d25e, title = {KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia}, author = {Malani, D; Yadav, B; Kumar, A; Potdar, S; Kontro, M; Kankainen, M; Javarappa, KK; Porkka, K; Wolf, M; Aittokallio, T; Wennerberg, K; Heckman, CA; Murumagi, A; Kallioniemi, O}, editor = {Porkka, Kimmo}, doi = {10.1038/s41375-020-0978-7}, issn = {0887-6924}, year = {2020}, date = {2020-01-01}, journal = {Leukemia}, volume = {34}, number = {10}, pages = {2780–2784}, publisher = {Nature Publishing Group}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 45. | Kallio, P; Jokinen, E; Hogstrom, J; Das, S; Heino, S; Lahde, M; Brodkin, J; Korhonen, EA; Alitalo, K Blocking Angiopoietin-2 Promotes Vascular Damage and Growth Inhibition in Mouse Tumors Treated with Small Doses of Radiation Journal Article In: Cancer Research, 80 (12), pp. 2639–2650, 2020, ISSN: 0008-5472. Links | iCAN PI: Alitalo, Kari @article{1960701eabc9482a94b681dd9fb89f25, title = {Blocking Angiopoietin-2 Promotes Vascular Damage and Growth Inhibition in Mouse Tumors Treated with Small Doses of Radiation}, author = {Kallio, P; Jokinen, E; Hogstrom, J; Das, S; Heino, S; Lahde, M; Brodkin, J; Korhonen, EA; Alitalo, K}, editor = {Alitalo, Kari}, doi = {10.1158/0008-5472.CAN-20-0497}, issn = {0008-5472}, year = {2020}, date = {2020-01-01}, journal = {Cancer Research}, volume = {80}, number = {12}, pages = {2639--2650}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 46. | Karademas, EC; Simos, P; Pat-Horenczyk, R; Roziner, I; Mazzocco, K; Sousa, B; Oliveira-Maia, AJ; Stamatakos, G; Cardoso, F; Frasquilho, D; Kolokotroni, E; Marzorati, C; Mattson, J; Pettini, G; Poikonen-Saksela, P In: Psycho-Oncology, 2021, ISSN: 1057-9249. Links | iCAN PI: Mattson, Johanna @article{0d00b1cb1f4d4603b7a1bc3bc7b061d2, title = {Cognitive, emotional, and behavioral mediators of the impact of coping self-efficacy on adaptation to breast cancer: An international prospective study}, author = {Karademas, EC; Simos, P; Pat-Horenczyk, R; Roziner, I; Mazzocco, K; Sousa, B; Oliveira-Maia, AJ; Stamatakos, G; Cardoso, F; Frasquilho, D; Kolokotroni, E; Marzorati, C; Mattson, J; Pettini, G; Poikonen-Saksela, P}, editor = {Mattson, Johanna}, doi = {10.1002/pon.5730}, issn = {1057-9249}, year = {2021}, date = {2021-01-01}, journal = {Psycho-Oncology}, publisher = {Wiley Blackwell}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 47. | Farkkila, A; Rodriguez, A; Oikkonen, J; Gulhan, DC; Nguyen, H; Dominguez, J; Ramos, S; Mills, CE; Perez-Villatoro, F; Lazaro, JB; Zhou, J; Clairmont, CS; Moreau, LA; Park, PJ; Sorger, PK; Hautaniemi, S; Frias, S; D'Andrea, AD Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells Journal Article In: Cancer Research, 81 (10), pp. 2774–2787, 2021, ISSN: 0008-5472. Links | iCAN PI: Färkkilä, Anniiina @article{a4f366b6987b4a20965378eeaf34edba, title = {Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells}, author = {Farkkila, A; Rodriguez, A; Oikkonen, J; Gulhan, DC; Nguyen, H; Dominguez, J; Ramos, S; Mills, CE; Perez-Villatoro, F; Lazaro, JB; Zhou, J; Clairmont, CS; Moreau, LA; Park, PJ; Sorger, PK; Hautaniemi, S; Frias, S; D'Andrea, AD}, editor = {Färkkilä, Anniiina}, doi = {10.1158/0008-5472.CAN-20-2912}, issn = {0008-5472}, year = {2021}, date = {2021-01-01}, journal = {Cancer Research}, volume = {81}, number = {10}, pages = {2774--2787}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 48. | Adnan-Awad, S; Kim, D; Hohtari, H; Javarappa, KK; Brandstoetter, T; Mayer, I; Potdar, S; Heckman, CA; Kytola, S; Porkka, K; Doma, E; Sexl, V; Kankainen, M; Mustjoki, S Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets Journal Article In: Leukemia, 35 (7), pp. 1964–1975, 2021, ISSN: 0887-6924. Abstract | Links | iCAN PI: Mustjoki, Satu @article{81309f44df9745a68145de5ccebea0de, title = {Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets}, author = {Adnan-Awad, S; Kim, D; Hohtari, H; Javarappa, KK; Brandstoetter, T; Mayer, I; Potdar, S; Heckman, CA; Kytola, S; Porkka, K; Doma, E; Sexl, V; Kankainen, M; Mustjoki, S}, editor = {Mustjoki, Satu}, doi = {10.1038/s41375-020-01082-4}, issn = {0887-6924}, year = {2021}, date = {2021-01-01}, journal = {Leukemia}, volume = {35}, number = {7}, pages = {1964--1975}, publisher = {Nature Publishing Group}, abstract = {The oncogenic protein Bcr-Abl has two major isoforms, p190Bcr-Abl and p210Bcr-Abl. While p210Bcr-Abl is the hallmark of chronic myeloid leukemia (CML), p190Bcr-Abl occurs in the majority of Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients. In CML, p190Bcr-Abl occurs in a minority of patients associating with distinct hematological features and inferior outcomes, yet the pathogenic role of p190Bcr-Abl and potential targeting therapies are largely uncharacterized. We employed next generation sequencing, phospho-proteomic profiling, and drug sensitivity testing to characterize p190Bcr-Abl in CML and hematopoietic progenitor cell line models (Ba/f3 and HPC-LSK). p190Bcr-Abl CML patients demonstrated poor response to imatinib and frequent mutations in epigenetic modifiers genes. In contrast with p210Bcr-Abl, p190Bcr-Abl exhibited specific transcriptional upregulation of interferon, interleukin-1 receptor, and P53 signaling pathways, associated with hyperphosphorylation of relevant signaling molecules including JAK1/STAT1 and PAK1 in addition to Src hyperphosphorylation. Comparable to p190Bcr-Abl CML patients, p190Bcr-Abl cell lines demonstrated similar transcriptional and phospho-signaling signatures. With the drug sensitivity screening we identified targeted drugs with specific activity in p190Bcr-Abl cell lines including IAP-, PAK1-, and Src inhibitors and glucocorticoids. Our results provide novel insights into the mechanisms underlying the distinct features of p190Bcr-Abl CML and promising therapeutic targets for this high-risk patient group.}, keywords = {}, pubstate = {published}, tppubtype = {article} } The oncogenic protein Bcr-Abl has two major isoforms, p190Bcr-Abl and p210Bcr-Abl. While p210Bcr-Abl is the hallmark of chronic myeloid leukemia (CML), p190Bcr-Abl occurs in the majority of Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) patients. In CML, p190Bcr-Abl occurs in a minority of patients associating with distinct hematological features and inferior outcomes, yet the pathogenic role of p190Bcr-Abl and potential targeting therapies are largely uncharacterized. We employed next generation sequencing, phospho-proteomic profiling, and drug sensitivity testing to characterize p190Bcr-Abl in CML and hematopoietic progenitor cell line models (Ba/f3 and HPC-LSK). p190Bcr-Abl CML patients demonstrated poor response to imatinib and frequent mutations in epigenetic modifiers genes. In contrast with p210Bcr-Abl, p190Bcr-Abl exhibited specific transcriptional upregulation of interferon, interleukin-1 receptor, and P53 signaling pathways, associated with hyperphosphorylation of relevant signaling molecules including JAK1/STAT1 and PAK1 in addition to Src hyperphosphorylation. Comparable to p190Bcr-Abl CML patients, p190Bcr-Abl cell lines demonstrated similar transcriptional and phospho-signaling signatures. With the drug sensitivity screening we identified targeted drugs with specific activity in p190Bcr-Abl cell lines including IAP-, PAK1-, and Src inhibitors and glucocorticoids. Our results provide novel insights into the mechanisms underlying the distinct features of p190Bcr-Abl CML and promising therapeutic targets for this high-risk patient group. |
| 49. | Vajavaara, H; Mortensen, JB; Leivonen, SK; Hansen, IM; Ludvigsen, M; Holte, H; Jorgensen, J; Bjerre, M; d'Amore, F; Leppa, S Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma Journal Article In: Cancers, 13 (3), 2021, ISSN: 2072-6694. @article{894b374e16e5411dbf75f576628cc793, title = {Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma}, author = {Vajavaara, H; Mortensen, JB; Leivonen, SK; Hansen, IM; Ludvigsen, M; Holte, H; Jorgensen, J; Bjerre, M; d'Amore, F; Leppa, S}, editor = {Leppä, Sirpa}, doi = {10.3390/cancers13030398}, issn = {2072-6694}, year = {2021}, date = {2021-01-01}, journal = {Cancers}, volume = {13}, number = {3}, publisher = {MDPI}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 50. | Douglas, SPM; Siipola, P; Kovanen, PE; Pyorala, M; Kakko, S; Savolainen, ER; Salmenniemi, U; Orte, K; Kytola, S; Pitkanen, E; Porkka, K; Kilpivaara, O; Wartiovaara-Kautto, U ERCC6L2 defines a novel entity within inherited acute myeloid leukemia Journal Article In: Blood, 133 (25), pp. 2724–2728, 2019, ISSN: 0006-4971. Links | iCAN PI: Wartiovaara-Kautto, Ulla @article{166622499eff46959296914376040882, title = {ERCC6L2 defines a novel entity within inherited acute myeloid leukemia}, author = {Douglas, SPM; Siipola, P; Kovanen, PE; Pyorala, M; Kakko, S; Savolainen, ER; Salmenniemi, U; Orte, K; Kytola, S; Pitkanen, E; Porkka, K; Kilpivaara, O; Wartiovaara-Kautto, U}, editor = {Wartiovaara-Kautto, Ulla}, doi = {10.1182/blood-2019-01-896233}, issn = {0006-4971}, year = {2019}, date = {2019-01-01}, journal = {Blood}, volume = {133}, number = {25}, pages = {2724--2728}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 51. | Mehine, M; Khamaiseh, S; Ahvenainen, T; Heikkinen, T; Ayravainen, A; Pakarinen, P; Harkki, P; Pasanen, A; Butzow, R; Vahteristo, P 3 ' RNA Sequencing Accurately Classifies Formalin-Fixed Paraffin-Embedded Uterine Leiomyomas Journal Article In: Cancers, 12 (12), 2020, ISSN: 2072-6694. Links | iCAN PI: Vahteristo, Pia @article{14ae6d76b9ff4bc8ab6bbb6fdd348d4d, title = {3 ' RNA Sequencing Accurately Classifies Formalin-Fixed Paraffin-Embedded Uterine Leiomyomas}, author = {Mehine, M; Khamaiseh, S; Ahvenainen, T; Heikkinen, T; Ayravainen, A; Pakarinen, P; Harkki, P; Pasanen, A; Butzow, R; Vahteristo, P}, editor = {Vahteristo, Pia}, doi = {10.3390/cancers12123839}, issn = {2072-6694}, year = {2020}, date = {2020-01-01}, journal = {Cancers}, volume = {12}, number = {12}, publisher = {MDPI}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 52. | Bergroth, R; Matikainen, M; Rannikko, A Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up Journal Article In: European urology open science, 28 , pp. 43–46, 2021, ISSN: 2666-1691. Links | iCAN PI: Rannikko, Antti @article{ec573f27d54f4d1d81137843e4e1ece2, title = {Mobile PSA: A Novel Telehealth Tool for Prostate Cancer Follow-Up}, author = {Bergroth, R; Matikainen, M; Rannikko, A}, editor = {Rannikko, Antti}, doi = {10.1016/j.euros.2021.04.004}, issn = {2666-1691}, year = {2021}, date = {2021-01-01}, journal = {European urology open science}, volume = {28}, pages = {43--46}, publisher = {Elsevier}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
| 53. | Mulder, RL; Font-Gonzalez, A; Green, DM; Loeffen, EAH; Jacqueline, MMH; Loonen, J; Yu, RC; Ginsberg, JP; Mitchell, RT; Byrne, J; Skinner, R; Anazodo, A; Constine, LS; de Vries, A; Jahnukainen, K; Lorenzo, A; Meissner, A; Nahata, L; Dinkelman-Smit, M; Tournaye, H; Haupt, R; Heuvel-Eibrink, MMV; Santen, HMV; Pelt, AMMV; Dirksen, U; den Hartogh, J; van Dulmen-den Broeder, E; Wallace, WH; Levine, J; Tissing, WJE; Kremer, LCM; Kenney, LB; Van de Wetering, MD In: Lancet Oncology, 22 (2), pp. E57–E67, 2021, ISSN: 1470-2045. Links | iCAN PI: Jahnukainen, Kirsi @article{d11d3febb05a41e4a651066c9b3b5ef7, title = {Fertility Preservation in Childhood, Adolescent, and Young Adult Cancer 2 Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group}, author = {Mulder, RL; Font-Gonzalez, A; Green, DM; Loeffen, EAH; Jacqueline, MMH; Loonen, J; Yu, RC; Ginsberg, JP; Mitchell, RT; Byrne, J; Skinner, R; Anazodo, A; Constine, LS; de Vries, A; Jahnukainen, K; Lorenzo, A; Meissner, A; Nahata, L; Dinkelman-Smit, M; Tournaye, H; Haupt, R; Heuvel-Eibrink, MMV; Santen, HMV; Pelt, AMMV; Dirksen, U; den Hartogh, J; van Dulmen-den Broeder, E; Wallace, WH; Levine, J; Tissing, WJE; Kremer, LCM; Kenney, LB; Van de Wetering, MD}, editor = {Jahnukainen, Kirsi}, doi = {10.1016/S1470-2045(20)30582-9}, issn = {1470-2045}, year = {2021}, date = {2021-01-01}, journal = {Lancet Oncology}, volume = {22}, number = {2}, pages = {E57--E67}, publisher = {EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC}, keywords = {}, pubstate = {published}, tppubtype = {article} } |